Please assess the completion status of the following clinical trial:

Trial Title: Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive postmenopausal women~* Diagnosed hypertension (grade 1 or 2 according to ESH/ESC 2013 guidelines)~Exclusion Criteria:~* breast cancer in a first-degree relative~* hyperplasia diagnosed by endometrial biopsy,~* history of thromboembolic diseases,~* current or history of use of estrogen-progestin therapy or contraceptives~* diabetes,~* kidney failure,~* thyroid disease,~* heart and other chronic diseases (secondary hypertension, atrial fibrillation)

- Gender: FEMALE
- Minimum Age: 49 Years
- Maximum Age: 53 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Control group consisted of 40 postmenopausal women with normal blood pressure.
- Hypertensive women group receiving hydrochlorothiazide (Type: EXPERIMENTAL): Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
- Hypertensive women group receiving perindopril. (Type: EXPERIMENTAL): Patients received perindopril 4 mg/day p.o for 1 year.
- Hypertensive women group receiving hydrochlorothiazide and EPT (Type: EXPERIMENTAL): Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
- Hypertensive women group receiving perindopril and EPT. (Type: EXPERIMENTAL): Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
- Hipotensive women group receiving EPT. (Type: EXPERIMENTAL): Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).